Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow OLMA by emailGet an email when OLMA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about OLMA, unsubscribe in one click. Privacy
📣 What OLMA Says Is Next
first quarter of 2027 · “Importantly, enrollment in our pivotal OPERA-01 Phase 3 trial is complete and we now expect to report top-line data in the first quarter of 2027,” said Sean P.”
Company press release, Aug 10, 2026 · SEC filing
first quarter of 2027 · “Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027”
Company press release, Aug 10, 2026 · SEC filing
H2 2026 · “Study to evaluate OP-3136, Olema’s novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026”
Company press release, May 26, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full OLMA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OLMA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.